Royal Bank of Canada Reaffirms Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating reiterated by Royal Bank of Canada in a note issued to investors on Tuesday,Benzinga reports. They currently have a $11.00 price objective on the biotechnology company’s stock, up from their previous price objective of $10.00. Royal Bank of Canada’s price objective would suggest a potential upside of 31.58% from the stock’s previous close.

Several other equities research analysts also recently issued reports on BCRX. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday. They issued an “outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $8.36 on Tuesday. The firm has a 50-day moving average of $8.07 and a 200-day moving average of $7.85. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $9.50. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -13.70 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same period last year, the company posted $0.28 EPS. BioCryst Pharmaceuticals’s revenue was up 40.8% on a year-over-year basis. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $33,000. Venturi Wealth Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $46,000. R Squared Ltd bought a new position in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $48,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the period. Finally, KBC Group NV increased its holdings in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 4,537 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.